Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
Derikx LAAP, Dolby HW, Plevris N, Lucaciu L, Rees CS, Lyons M, Siakavellas SI, Constantine-Cooke N, Jenkinson P, Su S, O'Hare C, Kirckpatrick L, Merchant LM, Noble C, Arnott ID, Jones GR, Lees CW.
Derikx LAAP, et al. Among authors: lucaciu l.
J Crohns Colitis. 2021 Dec 18;15(12):2011-2021. doi: 10.1093/ecco-jcc/jjab100.
J Crohns Colitis. 2021.
PMID: 34089587
Free PMC article.